arrow
A

Amanda Littlewood-Evans

Novartis
H指数:29
被引数:3,415

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab
2023-02-0114
PRE
Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events
2023-02-0115
PRE
Nonhematopoietic IRAK1 drives arthritis via chemoattractants
2022-07-083
OA
Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A4 Hydrolase
2021-02-1624
PREAI
Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure
2020-08-2822
PREAI
Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology
2020-04-3033
OAAI
Requirement of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Protease Activity for Fcγ Receptor-Induced Arthritis, but Not Fcγ Receptor-Mediated Platelet Elimination, in Mice
2020-04-269
PREAI
Small-molecule factor B inhibitor for the treatment of complement-mediated diseases
2019-03-29153
OAAI
Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors

CDZ173 (Leniolisib) 的发现,代表了一类结构新颖的PI3K δ 选择性抑制剂

2017-09-0586
OAAI
Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis

对伤害感受,炎症和血管生成具有调节作用的有效和口服活性的GPR4拮抗剂的设计和合成

2017-08-0122
PREAI
A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis
2015-12-2135
PREAI